Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycophenolate mofetil vs cyclophosphamide for induction and maintenance in lupus nephritis
2004-004917-41Phase 3Completed
- Sponsor
- Aspreva Pharmaceuticals
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of mycophenolate mofetil in lupus nephritis (LN) (2 arms), sponsored by Aspreva Pharmaceuticals. Primary endpoint: Induction response rate (MMF vs cyclophosphamide). Started Jul 2005; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2004-004917-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004917-41.